AlphaCentric Advisors LLC - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 95 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2020. The put-call ratio across all filers is 0.41 and the average weighting 0.3%.

Quarter-by-quarter ownership
AlphaCentric Advisors LLC ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q3 2023$412,800
-18.9%
15,0000.0%0.23%
-17.0%
Q2 2023$508,950
-5.7%
15,0000.0%0.28%
-24.2%
Q1 2023$539,700
-19.3%
15,0000.0%0.37%
-43.7%
Q4 2022$668,550
+39.9%
15,000
-11.8%
0.66%
+34.6%
Q3 2022$478,000
-27.2%
17,0000.0%0.49%
+157.1%
Q4 2021$657,000
-28.4%
17,0000.0%0.19%
-18.0%
Q3 2021$918,000
+9.8%
17,000
-32.0%
0.23%
+2.6%
Q2 2021$836,000
+62.3%
25,0000.0%0.23%
+30.5%
Q1 2021$515,000
+744.3%
25,000
+614.3%
0.17%
+596.0%
Q4 2020$61,000
+17.3%
3,5000.0%0.02%0.0%
Q3 2020$52,0003,5000.02%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q3 2020
NameSharesValueWeighting ↓
Kynam Capital Management, LP 2,600,000$88,218,00012.13%
Octagon Capital Advisors LP 759,898$25,783,3393.59%
TSP Capital Management Group, LLC 251,895$8,546,8003.08%
ACUTA CAPITAL PARTNERS, LLC 122,343$4,151,0982.81%
5AM Venture Management, LLC 310,270$10,527,4612.62%
COMMODORE CAPITAL LP 631,665$21,432,3932.41%
RTW INVESTMENTS, LP 3,463,201$117,506,4102.24%
Eversept Partners, LP 785,740$26,660,1582.23%
Redmile Group, LLC 1,696,004$57,545,4162.21%
Affinity Asset Advisors, LLC 87,031$2,952,9621.03%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders